Group 2 was treated with HA, at a molecular weight of 3.010 Da and a concentration of 10 mg/mL, delivering a dose of 6 mg per injection
This modification reduces the binding capacity of Kelch-like ECH-associated protein 1 (Keap1) to Nrf2, downregulates the ubiquitination and degradation of Nrf2, enhances the stability of Nrf2, and thereby inhibits ferroptosis
Survodutide and orforglipron represent additional emerging molecules in this space, with orforglipron being particularly notable as an oral non-peptide GLP-1 agonist
8 Lifestyle interventions are also effective in reducing the incidence of pregnancy complications in pregnant women with obesity, but tend to induce only modest improvements in offspring cardiovascular outcomes without reducing adiposity
[DOI] [PMC free article] [PubMed] [Google Scholar] 217.Hodgetts K., Howes L., Fang Y.Y., Song Z.M